Using EEG Biomarkers to Accelerate Early Drug Development in Fragile X Syndrome & Autism

• Demonstrating how resting-state EEG can serve as a sensitive translational measure of target engagement in small first-in-human Fragile X and autism studies
• Presenting evidence of rapid normalization of disease-relevant EEG abnormalities following acute and short-erm treatment with novel synaptic therapeutics
• Pairing EEG biomarker improvements with clinically meaningful cognitive outcomes, including NIH Toolbox measures, to strengthen early proof-of-concept decisions
• Leveraging translational biomarker platforms to improve confidence in mechanism validation and subsequent clinical development decisions

Speakers:

Craig Erickson

Associate Professor

Cincinnati Children’s Hospital